Abstract: An aerosol generating device includes a housing including an accommodation space in which an aerosol generating article is accommodated and an air flow path through which fluid moves inside the housing, wherein a volume of the air flow path is variable.

Abstract: An aerosol generating device includes: a housing including a hole for receiving an aerosol generating article and a guide apart from the hole; and a cover configured to move along the guide between a first position and a second position to open or close the hole, wherein the hole is open when the cover is located in the first position, and the hole is closed when the cover is located in the second position.

Abstract: In an embodiment a method includes manufacturing a membrane-electrode-gas diffusion layer assembly (MEGA) fabric by bonding a gas diffusion layer (GDL) material to a first surface of a membrane-electrode assembly (MEA) fabric, injecting, by a steam injector, a liquid material to a first surface of the MEGA fabric while allowing the liquid material to be absorbed to the first surface of the MEGA fabric, supplying, by a gas injector, compressed gas to a second surface of the MEGA fabric in which the liquid material has been absorbed, inspecting, by a surface inspection device, a surface state of the MEGA fabric after supplying the compressed gas and, after inspecting, winding the MEGA fabric around a MEGA winding unit.

Abstract: One aspect provides a pharmaceutical composition and a pharmaceutical combination formulation contains the same, the pharmaceutical composition containing as active ingredients: a proton pump inhibitor or a pharmaceutically acceptable salt thereof; and an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

Abstract: A device is provided for performing a pressure test on a battery module. The device may include a module case in which battery cells are accommodated, a pressure plate installed in a middle portion of the module case in a width direction and configured to pressurize the battery cells toward the module case, a pressure driver configured to apply a pressure to the pressure plate, and a controller configured to control a pressure force and a pressure pattern with respect to the battery cells. The pressure plate may be configured to simulate expansion and contraction of the battery cells by repeatedly pressurizing and depressurizing the battery cells.

Abstract: Provided are a composite formulation including sitagliptin and dapagliflozin and a method of preparing the same.

Abstract: Provided are a pharmaceutical composite formulation and a method of preparing the same, the pharmaceutical composite formulation including: a first layer containing, as an active ingredient, a proton pump inhibitor or a pharmaceutically acceptable salt thereof and a lubricant, and a second layer containing, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, and a mixture thereof.

Abstract: According to an aspect, provided are a composite tablet and a method of preparing the composite tablet, wherein the composite tablet may include a first layer including dry granules that include sitagliptin or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and dapagliflozin or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a second layer including wet granules that include metformin or a pharmaceutically acceptable salt thereof and colloidal silicon dioxide.

Abstract: An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

Abstract: The present invention relates to a pharmaceutical preparation comprising a granule comprising a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a diluent. The pharmaceutical preparation has a high productivity of the preparation due to excellent tableting properties, friability, and mass uniformity. The pharmaceutical preparation has low generated amount of impurities and high stability.

Abstract: Disclosed are an acid-resistant pharmaceutical composition including tamsulosin hydrochloride, and a method of preparing the same. The pharmaceutical composition is formulated into tablets by preparing core beads including tamsulosin hydrochloride as an active ingredient, coating the core beads with an entering coating solution including a specific amount of plasticizer, adding a post mixture portion including a buffer to adjust density and a lubricant to the enteric-coated core beads, and performing tableting. The enteric coating layer is not broken during the tableting process. Thus, the acid resistance of the pharmaceutical composition is maintained. The pharmaceutical composition can be easily formulated into tablets, ensures good uniformity of dosage unit, lowers dissolution rate of tamsulosin hydrochloride, has good acid resistance, and is stable not to exhibit signification decomposition of tamsulosin hydrochloride.

Abstract: A semiconductor light emitting device includes a plurality of light emitting structures, an isolation layer covering side surfaces of the plurality of light emitting structures and insulating the plurality of light emitting structures from one another, a partition layer formed on the isolation layer, a first protective layer covering top surfaces of the plurality of light emitting structures and side walls of the partition layer, a reflective layer covering the first protective layer and disposed on the side walls of the partition layer, and a second protective layer covering the reflective layer.

Abstract: Provided is an oral pharmaceutical formulation including sustained-release pellets containing tamsulosin hydrochloride and a pharmaceutically acceptable additive, wherein the sustained-release pellets includes about 50 wt % to about 100 wt % of particles having a particle size of about 0.50 mm to about 0.85 mm, and less than about 15 wt % of particles having a particle size less than about 0.50 mm. The oral pharmaceutical formulation may have a reduced deviation in dissolution rate of tamsulosin hydrochloride and improved content uniformity among unit dosage forms, and have ensured quality due to high reproducibility of unit dosage forms.

Abstract: A battery module includes a plurality of secondary batteries, each including an electrode assembly and an electrolyte accommodated in an inner space of an exterior case. The battery module also includes an electrode lead having a body and a plate-shaped head portion. A first end of the body is electrically connected to a positive electrode plate or the a negative electrode plate of the electrode assembly, and a second end of the body protrudes outward from the exterior case. The plate-shaped head extends in both directions perpendicular to the protruding direction of the body from the second end. The battery module also includes a bus bar having a plate shape with a slit extending inwardly from one end thereof so as to receive a portion of the body. The electrode lead and the bus bar may be at least partially made of an electrically conductive material.

Abstract: Provided are a pharmaceutical composition including a core in a form of a multi-unit spheroidal tablet (MUST) containing esomeprazole or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is dissolved by 50 percent (%) or more within 15 minutes of an in vitro dissolution test; and a method of preparing the pharmaceutical composition. According to this, in case that the pharmaceutical composition is developed as the multi-unit spheroidal tablet, the dissolution may be accelerated in a condition of a slow stirring rate than that of a conventional pellet formulation or single tablet. Also, proton pump inhibitors (PPI)-based drugs including esomeprazole may be dissociated by gastric acid having a low pH, consequently inducing a decrease in bioavailability of the drug, but the pharmaceutical composition according to this may be minimize this.

Abstract: A semiconductor light emitting device includes a plurality of light emitting structures, an isolation layer covering side surfaces of the plurality of light emitting structures and insulating the plurality of light emitting structures from one another, a partition layer formed on the isolation layer, a first protective layer covering top surfaces of the plurality of light emitting structures and side walls of the partition layer, a reflective layer covering the first protective layer and disposed on the side walls of the partition layer, and a second protective layer covering the reflective layer.

Abstract: In some examples, a semiconductor device may comprise a semiconductor chip including a plurality of pixels, each pixel formed of a plurality of sub-pixels, such as a red sub-pixel, green sub-pixel and blue sub-pixel. Each sub-pixel may comprise a light emitting diode. A first signal line may connect to signal terminals of a first group sub-pixels (e.g., arranged in the same row), and a second signal line may connect to common terminals of a second group of sub-pixels (e.g., arranged in the same column). The number of chip pads may thus be reduced to provide increased design flexibility in location and/or allowing an increase in chip pad size. In some examples, a light transmissive material may be formed in openings of a semiconductor growth substrate on which light emitting cells of the sub-pixels were grown. The light transmissive material of some of the sub-pixels may comprise a wavelength conversion material and/or filter.

Abstract: A light emitting device package including a cell array including first, second and third light emitting devices each including a first conductivity-type semiconductor layer, an active layer, and a second conductivity-type semiconductor layer, the cell array having a first surface and a second surface opposing the first surface, a light-transmissive substrate including a first wavelength conversion portion and a second wavelength conversion portion corresponding to the first light emitting device and the second light emitting device, respectively, and bonded to the first surface, and a eutectic bonding layer including a first light emitting window, a second light emitting window and a third light emitting window corresponding to the first light emitting device, the second light emitting device and the third light emitting device, respectively, and bonding the light-transmissive substrate and the first to third light emitting devices to each other may be provided.

Abstract: A pharmaceutical formulation for oral administration with a controlled dissolution rate is provided. The formulation contains Tamsulosin hydrochloride-containing sustained-release pellets. The sustained-release pellets include (i) a Tamsulosin hydrochloride, (ii) hydroxypropyl methylcellulose (HPMC), (iii) an acid-resistant acryl polymer, and (iv) two or more kinds of insoluble diluents. A preparation method of the formulation is provided.

Abstract: A chip mounting method includes providing a first substrate including a light transmissive substrate having first and second surfaces, a sacrificial layer provided on the first surface, and a plurality of chips bonded to the sacrificial layer, obtaining first mapping data by testing the chips, the first mapping data defining coordinates of normal chips and defective chips among the chips, disposing a second substrate below the first surface, disposing the normal chips on the second substrate by radiating a first laser beam to positions of the sacrificial layer corresponding to the coordinates of the normal chips, based on the first mapping data, to remove portions of the sacrificial layer thereby separating the normal chips from the light transmissive substrate, and mounting the normal chips on the second substrate by radiating a second laser beam to a solder layer of the second substrate.